Pregled bibliografske jedinice broj: 546555
Lapatinib in the treatment of HER-2 overexpressing breast cancer
Lapatinib in the treatment of HER-2 overexpressing breast cancer // Journal of Balkan Union of Oncology, 16 (2011), 3; 393-399 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 546555 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Lapatinib in the treatment of HER-2 overexpressing
breast cancer
Autori
Vrdoljak, Eduard ; Boban, Marijo ; Ban, Marija
Izvornik
Journal of Balkan Union of Oncology (1107-0625) 16
(2011), 3;
393-399
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
breast cancer ; HER-2 ; lapatinib ; targeted therapy
Sažetak
Lapatinib is the only clinically available agent for the treatment of patients with human epidermal growth factor receptor-2 (HER-2) positive tumors that have progressed on treatment with trastuzumab, taxanes and anthracyclines. Moreover, when given with letrozole in postmenopausal patients with estrogen receptor (ER) and HER-2 positive disease it induces clinically meaningful benefit. Recently presented neoadjuvant data suggests an important place for the combination of trastuzumab and lapatinib in the therapy of early HER-2 positive breast cancer. This article reviews the current status and future perspectives of lapatinib.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
MZOS-216-0000000-0484 - Dvostruki model ovarijalne kancerogeneze - molekularna i morfološka studija (Tomić, Snježana, MZOS ) ( CroRIS)
Ustanove:
KBC Split,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
